391MO Phase III randomized IRIGA trial of FOLFIRINOX versus mFOLFOX6 as first-line treatment for patients with HER2-negative gastric and gastroesophageal adenocarcinoma
Titel:
391MO Phase III randomized IRIGA trial of FOLFIRINOX versus mFOLFOX6 as first-line treatment for patients with HER2-negative gastric and gastroesophageal adenocarcinoma
Auteur:
Gavrilova, D. Besova, N. Obarevich, E. Artamonova, E. Makiev, G.G. Abdulaeva, R.S. Guzhavin, D.P. Karasev, I. Kolobanova, E. Sun, H. Yugay, V. Kalinin, O. Chernich, M. Salimova, A.A. Shalenkov, V. Stilidi, I. Fedyanin, M. Tryakin, A.